Conference Coverage

Use Of Lavender Oil for Treating Cutaneous Erythema and Paresthesia Symptoms Related to Subcutaneous Chemotherapy Injections in Cancer Patients in an Outpatient Oncology Clinic

Blood JE, Swenson MS.

Abstract 4: 2014 AVAHO Meeting


 

References

Purpose: Adverse effects (AEs) related to chemotherapy treatment are an ongoing area of concern. Skin reaction is a common AE related to subcutaneous chemotherapy injections. About 77% of patients will have skin reactions during treatment. Lavender oil (lavandula angustifolia) or true lavender has been shown to have a healing effect on skin issues such as the healing of burns and conditions involving skin inflammation, including dermatitis, eczema, psoriasis, boils, and wounds. The chemical components of lavender have antiphlogistic, analgesic, and cytophylactic properties. Positive patient outcomes have been documented in a pilot study of the topical application of 3% lavender oil in coconut carrier oil for cutaneous erythema related to subcutaneous chemotherapy injections.

Methods: Patient skin reactions were photo-documented throughout treatment, and logs were kept by each patient to document the home application of lavender. A numerical grading scale was used to evaluate the degree of erythema.

Results: The results were a significant decrease in erythema and self-reported relief of associated burning and paresthesia, which supports the hypothesis that lavender oil potentially is an effective treatment for erythema and paresthesia related to injection reaction.

Conclusions: These findings confirm the feasibility for further research to support the efficacy of treatment with lavender oil. Further studies are needed to establish a standard of practice.

Recommended Reading

Interfacing Medicine and Social Work at the VA for Improved Patient Outcomes
Federal Practitioner
Development and Implementation of an Oral Antitumor Outpatient Clinic
Federal Practitioner
Survivorship Care Plan for the Veteran Diagnosed With Kidney Cancer
Federal Practitioner
Role of Prophylactic PEG and Risk Factors for PEG Dependency in the Veteran Population
Federal Practitioner
Protocol to Evaluate Medication Nonadherence Among Patients with Metastatic Prostate Cancer
Federal Practitioner
Chemotherapy Dosing for Overweight and Obese Adult Patients With Cancer
Federal Practitioner
Improving Communication on Intent-of-Chemotherapy, Using QOPI Scores and PDSA Cycles
Federal Practitioner
Use of Telehealth Clinic in Radiation Oncology for Prostate Cancer Follow-Up
Federal Practitioner
Outcomes of Screening for Distress in Veterans with Cancer
Federal Practitioner
Setting up a Cancer Genetic Risk Evaluation Clinic in a VAMC
Federal Practitioner